Consainsights logo
Reports / Rubella Vaccine (Human Diploid Cell) Market

Rubella Vaccine (Human Diploid Cell) Market

Rubella Vaccine (Human Diploid Cell) Market Research Report – Segmented By End User (ADULT RUBELLA (HUMAN DIPLOID CELL) VACCINE, PEDIATRIC RUBELLA (HUMAN DIPLOID CELL) VACCINE, TRAVELER RUBELLA (HUMAN DIPLOID CELL) VACCINE), Region (ASIA-PACIFIC, EUROPE, LAMEA) & Region (North America, Europe, APAC, Latin America, Middle East and Africa) – Analysis on Size, Share, Trends, COVID-19 Impact, Competitive Analysis, Growth Opportunities and Key Insights from 2017 to 2026.


01

Executive Summary

Rubella Vaccine (Human Diploid Cell) Market was valued at US $79.80 million in 2021 and is projected to grow at 4.99% CAGR over the forecast period to reach US $106.90 million by 2027. Rubella Vaccine (Human Diploid Cell) Market represented US $7.41 million opportunity over 2019-2021 and estimated to create US $27.10 million opportunity in 2027 over 2021.

Rubella Vaccine (Human Diploid Cell) from Consainsights analyses the Rubella Vaccine (Human Diploid Cell) Market in the Life Sciences industry over the forecast period to 2027.

Rubella Vaccine (Human Diploid Cell) research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Rubella Vaccine (Human Diploid Cell) segmentation includes End User, Region and Geography.

Based on the End User, the Rubella Vaccine (Human Diploid Cell) analysis covers PEDIATRIC RUBELLA (HUMAN DIPLOID CELL) VACCINE, ADULT RUBELLA (HUMAN DIPLOID CELL) VACCINE, TRAVELER RUBELLA (HUMAN DIPLOID CELL) VACCINE.

In End User segment, PEDIATRIC RUBELLA (HUMAN DIPLOID CELL) VACCINE segment has highest cagr growth of 4.43%.

Based on the Region, the Rubella Vaccine (Human Diploid Cell) analysis covers EUROPE, ASIA-PACIFIC, LAMEA.

In Region segment, EUROPE segment has highest cagr growth of 4.43%.

Based on the region, the Rubella Vaccine (Human Diploid Cell) analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include MERCK & CO., INC., GLAXOSMITHKLINE PLC, CHIRON CORPORATION (NOVARTIS), SANOFI-AVENTIS, SERUM INSTITUTE OF INDIA, BERNA BIOTECH (CRUCELL), ASTELLAS PHARMA INC., ASTRAZENECA PLC. (MEDIMMUNE, LLC.), CSL LIMITED, PFIZER INC. and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

  • Revenue Share (%), By End User (2021)
    Revenue Share (%), By End User (2021)
  • Revenue Share (%), By Region (2021)
    Revenue Share (%), By Region (2021)
02

Market Overview

  • The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.
  • The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.
  • The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.
  • Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.
  • Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.
  • As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.
  • The currency used in this report is USD, with the market size indicated in terms of USD million/billion.
  • For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.
  • For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.
03

By End User

  • PEDIATRIC RUBELLA (HUMAN DIPLOID CELL) VACCINE accounted for US$40.71 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • ADULT RUBELLA (HUMAN DIPLOID CELL) VACCINE accounted for US$20.26 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • TRAVELER RUBELLA (HUMAN DIPLOID CELL) VACCINE accounted for US$18.82 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Rubella Vaccine (Human Diploid Cell) Market Y-o-Y Growth (USD million), By End User 2019 - 2027
Rubella Vaccine (Human Diploid Cell) Market Y-o-Y Growth (USD million), By End User 2019 - 2027
Rubella Vaccine (Human Diploid Cell) Market Size, By End User, 2019-2027 (USD million)
Rubella Vaccine (Human Diploid Cell) Market Size, By End User, 2019-2027 (USD million)

The ADULT RUBELLA (HUMAN DIPLOID CELL) VACCINE segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

ADULT RUBELLA (HUMAN DIPLOID CELL) VACCINE: global Rubella Vaccine (Human Diploid Cell) Market Revenue Opportunity (Us$ Mn)
ADULT RUBELLA (HUMAN DIPLOID CELL) VACCINE: global Rubella Vaccine (Human Diploid Cell) Market Revenue Opportunity (Us$ Mn)

The PEDIATRIC RUBELLA (HUMAN DIPLOID CELL) VACCINE segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

PEDIATRIC RUBELLA (HUMAN DIPLOID CELL) VACCINE: global Rubella Vaccine (Human Diploid Cell) Market Revenue Opportunity (Us$ Mn)
PEDIATRIC RUBELLA (HUMAN DIPLOID CELL) VACCINE: global Rubella Vaccine (Human Diploid Cell) Market Revenue Opportunity (Us$ Mn)

The TRAVELER RUBELLA (HUMAN DIPLOID CELL) VACCINE segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

TRAVELER RUBELLA (HUMAN DIPLOID CELL) VACCINE: global Rubella Vaccine (Human Diploid Cell) Market Revenue Opportunity (Us$ Mn)
TRAVELER RUBELLA (HUMAN DIPLOID CELL) VACCINE: global Rubella Vaccine (Human Diploid Cell) Market Revenue Opportunity (Us$ Mn)
04

By Region

  • EUROPE accounted for US$37.96 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • ASIA-PACIFIC accounted for US$37.62 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • LAMEA accounted for US$4.22 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Rubella Vaccine (Human Diploid Cell) Market Y-o-Y Growth (USD million), By Region 2019 - 2027
Rubella Vaccine (Human Diploid Cell) Market Y-o-Y Growth (USD million), By Region 2019 - 2027
Rubella Vaccine (Human Diploid Cell) Market Size, By Region, 2019-2027 (USD million)
Rubella Vaccine (Human Diploid Cell) Market Size, By Region, 2019-2027 (USD million)

The ASIA-PACIFIC segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

ASIA-PACIFIC: global Rubella Vaccine (Human Diploid Cell) Market Revenue Opportunity (Us$ Mn)
ASIA-PACIFIC: global Rubella Vaccine (Human Diploid Cell) Market Revenue Opportunity (Us$ Mn)

The EUROPE segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

EUROPE: global Rubella Vaccine (Human Diploid Cell) Market Revenue Opportunity (Us$ Mn)
EUROPE: global Rubella Vaccine (Human Diploid Cell) Market Revenue Opportunity (Us$ Mn)

The LAMEA segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

LAMEA: global Rubella Vaccine (Human Diploid Cell) Market Revenue Opportunity (Us$ Mn)
LAMEA: global Rubella Vaccine (Human Diploid Cell) Market Revenue Opportunity (Us$ Mn)
05

North America

  • In 2021, North America segment accounted for US$79.80 Bn and is expected grow with a CAGR of 4.99% over the forecast years.
  • In North America, United States accounted for US$45.68 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Canada accounted for US$34.11 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
North America Rubella Vaccine (Human Diploid Cell) Market, By Country, 2019-2027 (USD million)
North America Rubella Vaccine (Human Diploid Cell) Market, By Country, 2019-2027 (USD million)
North America Rubella Vaccine (Human Diploid Cell) Market - Market Opportunity (USD million), 2019, 2021 & 2027
North America Rubella Vaccine (Human Diploid Cell) Market - Market Opportunity (USD million), 2019, 2021 & 2027
Revenue Share (%), By End User - North America (2021)
Revenue Share (%), By End User - North America (2021)
Revenue Share (%), By Region - North America (2021)
Revenue Share (%), By Region - North America (2021)
North America Rubella Vaccine (Human Diploid Cell) Market, By Country, 2019-2027 (USD million)
North America Rubella Vaccine (Human Diploid Cell) Market, By Country, 2019-2027 (USD million)
United States Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
United States Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Canada Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Canada Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
06

Europe

  • In 2021, Europe segment accounted for US$79.80 Bn and is expected grow with a CAGR of 4.99% over the forecast years.
  • In Europe, Germany accounted for US$31.58 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • United Kingdom accounted for US$21.31 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • France accounted for US$11.14 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Spain accounted for US$7.45 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Russia accounted for US$4.67 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Italy accounted for US$3.36 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Rest of Europe accounted for US$0.29 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Europe Rubella Vaccine (Human Diploid Cell) Market, By Country, 2019-2027 (USD million)
Europe Rubella Vaccine (Human Diploid Cell) Market, By Country, 2019-2027 (USD million)
Europe Rubella Vaccine (Human Diploid Cell) Market - Market Opportunity (USD million), 2019, 2021 & 2027
Europe Rubella Vaccine (Human Diploid Cell) Market - Market Opportunity (USD million), 2019, 2021 & 2027
Revenue Share (%), By End User - Europe (2021)
Revenue Share (%), By End User - Europe (2021)
Revenue Share (%), By Region - Europe (2021)
Revenue Share (%), By Region - Europe (2021)
Europe Rubella Vaccine (Human Diploid Cell) Market, By Country, 2019-2027 (USD million)
Europe Rubella Vaccine (Human Diploid Cell) Market, By Country, 2019-2027 (USD million)
Germany Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Germany Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
United Kingdom Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
United Kingdom Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
France Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
France Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Spain Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Spain Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Russia Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Russia Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Italy Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Italy Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Rest of Europe Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Rest of Europe Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
07

Asia-Pacific

  • In 2021, Asia-Pacific segment accounted for US$79.80 Bn and is expected grow with a CAGR of 4.99% over the forecast years.
  • In Asia-Pacific, China accounted for US$33.02 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Japan accounted for US$22.07 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • India accounted for US$12.00 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Southeast Asia accounted for US$9.07 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Australia & New Zealand accounted for US$3.00 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Rest of Asia-Pacific accounted for US$0.63 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Asia-Pacific Rubella Vaccine (Human Diploid Cell) Market, By Country, 2019-2027 (USD million)
Asia-Pacific Rubella Vaccine (Human Diploid Cell) Market, By Country, 2019-2027 (USD million)
Asia-Pacific Rubella Vaccine (Human Diploid Cell) Market - Market Opportunity (USD million), 2019, 2021 & 2027
Asia-Pacific Rubella Vaccine (Human Diploid Cell) Market - Market Opportunity (USD million), 2019, 2021 & 2027
Revenue Share (%), By End User - Asia-Pacific (2021)
Revenue Share (%), By End User - Asia-Pacific (2021)
Revenue Share (%), By Region - Asia-Pacific (2021)
Revenue Share (%), By Region - Asia-Pacific (2021)
Asia-Pacific Rubella Vaccine (Human Diploid Cell) Market, By Country, 2019-2027 (USD million)
Asia-Pacific Rubella Vaccine (Human Diploid Cell) Market, By Country, 2019-2027 (USD million)
China Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
China Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Japan Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Japan Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
India Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
India Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Southeast Asia Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Southeast Asia Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Australia & New Zealand Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Australia & New Zealand Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Rest of Asia-Pacific Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Rest of Asia-Pacific Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
08

Middle East & Africa

Based on the Middle East & Africa, the Rubella Vaccine (Human Diploid Cell) Market analysis covers Middle East, Africa, Rest of Middle East & Africa.

Middle East & Africa Map
Middle East & Africa Rubella Vaccine (Human Diploid Cell) Market Size, 2019-2027 (Us$ Mn)
Middle East & Africa Rubella Vaccine (Human Diploid Cell) Size, 2019-2027 (Us$ Mn)
Middle East & Africa Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Middle East & Africa Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Middle East Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Middle East Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Africa Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Africa Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Rest of Middle East & Africa Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Rest of Middle East & Africa Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
09

Latin America

  • In 2021, Latin America segment accounted for US$79.80 Bn and is expected grow with a CAGR of 4.99% over the forecast years.
  • In Latin America, Brazil accounted for US$32.90 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Argentina accounted for US$20.56 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Mexico accounted for US$14.55 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Colombia accounted for US$9.90 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Rest of Latin America accounted for US$1.89 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Latin America Rubella Vaccine (Human Diploid Cell) Market, By Country, 2019-2027 (USD million)
Latin America Rubella Vaccine (Human Diploid Cell) Market, By Country, 2019-2027 (USD million)
Latin America Rubella Vaccine (Human Diploid Cell) Market - Market Opportunity (USD million), 2019, 2021 & 2027
Latin America Rubella Vaccine (Human Diploid Cell) Market - Market Opportunity (USD million), 2019, 2021 & 2027
Revenue Share (%), By End User - Latin America (2021)
Revenue Share (%), By End User - Latin America (2021)
Revenue Share (%), By Region - Latin America (2021)
Revenue Share (%), By Region - Latin America (2021)
Latin America Rubella Vaccine (Human Diploid Cell) Market, By Country, 2019-2027 (USD million)
Latin America Rubella Vaccine (Human Diploid Cell) Market, By Country, 2019-2027 (USD million)
Brazil Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Brazil Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Argentina Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Argentina Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Mexico Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Mexico Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Colombia Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Colombia Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Rest of Latin America Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Rest of Latin America Rubella Vaccine (Human Diploid Cell) Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
10

Company Analysis

  • MERCK & CO., INC.
  • GLAXOSMITHKLINE PLC
  • CHIRON CORPORATION (NOVARTIS)
  • SANOFI-AVENTIS
  • SERUM INSTITUTE OF INDIA
  • BERNA BIOTECH (CRUCELL)
  • ASTELLAS PHARMA INC.
  • ASTRAZENECA PLC. (MEDIMMUNE, LLC.)
  • CSL LIMITED
  • PFIZER INC.